Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data CYTOKINETICS INC files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
106
13.4
31.5
26.9
55.8
70.4
94.6
7.53
18.5
88
Research and development
59.9
90.3
89.1
86.1
97
160
241
330
339
416
General and administrative
27.8
36.5
31.3
39.6
52.8
96.8
178
174
215
284
Operating expenses
87.7
127
120
126
150
257
419
504
555
700
Operating income
18.7
-113
-88.9
-98.9
-93.9
-186
-324
-496
-536
-612
Interest expense
2.7
3.02
3.8
6.62
16
16.4
19.4
28.3
37.7
45.6
Interest income
0.45
4.2
4.5
5.3
1
11.4
Other non-operating income
0.46
2.6
4.19
4.54
5.33
0.33
11.3
27.6
51.5
48.4
Pre-tax income
16.5
-128
-106
Income tax
0
0
0
0
0
0
0
0
0
0
Net income
16.5
-128
-106
-122
-127
-215
-389
-526
-590
-785
EBITDA
19.4
-111
-87.7
-97.6
-92.1
-184
-318
-484
-527
-602
EPS, basic
0.41
-2.59
-1.95
-2.11
-1.97
-2.80
-4.33
-5.45
-5.26
-6.54
EPS, diluted
0.39
-2.59
-1.95
-2.11
-1.97
-2.80
-4.33
-5.45
-5.26
-6.54
Shares, basic (weighted)
39.9
49.4
0.05
0.06
0.06
0.08
0.09
0.1
0.11
0.12
Shares, diluted (weighted)
42.6
49.4
0.05
0.06
0.06
0.08
0.09
0.1
0.11
0.12
Balance sheet
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
66.9
125
42.3
36.4
83
113
65.6
113
94.9
123
Short-term investments
89.4
144
156
189
381
359
717
502
981
760
Receivables
0.02
1.11
2.23
5.16
4.42
51.8
0.15
1.28
16.7
17.8
Inventory
0
Other current assets
2.36
4.29
2.16
3.48
5.74
12.2
12.5
11.9
15.3
17
Total current assets
159
274
208
234
474
536
795
628
1,108
917
Property, plant and equipment
3.64
3.57
3.2
4.53
13.3
73.3
80.5
68.7
65.8
79.2
Lease right-of-use assets
2.92
73.1
82.7
79
75.2
76
Long-term investments
37
152
46.7
40.5
145
335
Other non-current assets
0.2
0.43
0.3
6.36
7.19
9.69
8
7.71
17.3
Total assets
170
295
211
290
534
841
1,015
824
1,402
1,425
Accounts payable
4.24
5.25
3.76
8.16
8.05
21.1
25.6
21.5
20.4
22.3
Accrued liabilities
18
17.4
15.8
12.1
19.3
34.4
44.1
42.6
55.3
83.3
Deferred revenue
8.06
0
0
0
52.4
1.61
Short-term debt
2.5
0
2.61
0
0
0.96
10.1
11.5
41.2
Total current liabilities
33.3
32.4
22.2
26
31.2
71.9
84.6
103
180
202
Long-term debt
27.4
31.8
39.8
45.1
46.2
47.4
63.8
58.4
93.2
246
Lease liabilities
0.77
2.2
0.44
112
127
120
113
108
Other non-current liabilities
0.14
1.1
0.77
0
4.46
1.04
0.19
0
Total liabilities
75.8
185
185
301
420
597
1,123
1,211
1,537
2,084
Total debt
29.9
31.8
42.4
45.1
46.2
47.4
650
639
620
288
Paid-in capital
612
756
769
853
1,105
1,452
1,482
1,726
2,564
2,826
Retained earnings
-518
-646
-743
-865
-992
-1,208
-1,586
-2,112
-2,702
-3,487
Other comprehensive income
0.14
0.34
0.5
0.68
0.15
-0.87
-3.59
-0.01
2.4
0.63
Shareholders' equity
94.4
110
25.9
-10.9
113
244
-108
-386
-135
-660
Total equity
94.4
110
25.9
-10.9
113
244
-108
-386
-135
-660
Total liabilities and equity
170
295
211
290
534
841
1,015
824
1,402
1,425
Shares outstanding
40.6
54
54.7
59.2
71
84.8
94.8
102
118
123
Cash flow statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
16.5
-128
-106
-122
-127
-215
-389
-526
-590
-785
Depreciation and amortization
0.74
1.92
1.24
1.29
1.83
2.28
5.81
11.9
9.53
10.1
Stock-based compensation
7.15
9.03
9.76
10.8
17.6
26.8
47.9
72.1
97.8
112
Deferred income tax
0
Change in receivables
-0.01
-1.09
-1.12
-2.93
0.74
-47.4
56.7
-1.14
-15.4
-1.11
Cash from operations
37
-102
-101
-90.9
8.94
-143
-300
-414
-396
-510
Capital expenditures
-1.6
-2.88
-0.89
-2.62
-11.1
-48.9
-11.3
-1.42
-3.91
-24.8
Purchases of investments
-145
-240
-240
-278
-436
-525
-855
-635
-1,293
-1,063
Sales and maturities of investments
246
203
247
423
605
871
744
1,104
Cash from investing
-52.1
-65.8
5.13
-74.7
-197
-148
-262
239
-553
16.7
Debt repaid
0
0
-47.7
0
-8.68
-10.8
Stock issued
0
112
0
36.2
0
0
164
Cash from financing
16.9
226
13.1
160
234
320
516
221
931
524
Exchange rate effect
-0.02
0.21
-0.72
Net change in cash
1.8
58.3
-83
-5.82
46.6
29.7
-45.5
46.2
-18.2
30.4
Free cash flow
35.4
-105
-102
-93.5
-2.11
-191
-311
-416
-400
-535
Interest paid
1.9
2.13
2.88
4.06
9.62
9.18
15.2
10.3
26
22.9
Income taxes paid
0
0
0
0
0
0
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $64.66 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Operating margin
-1,046.0%
Operating income / revenue.
EBITDA margin
-1,028.0%
EBITDA (operating income + depreciation and amortization) / revenue.
Net margin
-1,321.0%
Net income / revenue.
FCF margin
-858.2%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-820.8%
Cash from operations / revenue.
Return on assets (ROA)
-46.5%
Net income / average total assets.
R&D / revenue
586.6%
Research and development expense / revenue.
Stock-based pay / revenue
188.1%
Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue
37.3%
Capital expenditures / revenue.
D&A / revenue
18.5%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
376.6%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
-2.4%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
9.5%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
1.6%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
12.0%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
21.7%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
7.3%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
10.2%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
13.2%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
6.66x
Current assets / current liabilities.
Quick ratio
6.56x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
6.43x
(Cash + short-term investments) / current liabilities.
Debt / assets
14.3%
Total debt / total assets.
Liabilities / assets
109.0%
Total liabilities / total assets.
Net debt
-$890.1M
Total debt - cash - short-term investments. Negative means more cash than debt.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$512.32
Revenue / diluted weighted shares.
FCF per share
-$4,396.00
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$4,205.00
Cash from operations / diluted weighted shares.
Book value per share
-$1,313.00
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
133x
Market cap / revenue.
EV/Sales
120x
Enterprise value / revenue.
FCF yield
-6.5%
Free cash flow / market cap.
Earnings yield
-9.9%
Net income / market cap (the inverse of P/E).
What was CYTOKINETICS INC's revenue in fiscal 2025?
CYTOKINETICS INC reported revenue of $88.0M for fiscal 2025, 376.6% higher than the year before.
Was CYTOKINETICS INC profitable in fiscal 2025?
No. It reported a net loss of $785.0M.
How much free cash flow did CYTOKINETICS INC generate in fiscal 2025?
Cash from operations of $510.0M minus capital expenditures of $24.8M left free cash flow of -$534.8M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.